News
NXTC
--
0.00%
--
NextCure appoints new chief medical officer
NextCure (NXTC) appoints Dr. Han Myint, MD, FACP as chief medical officer. Prior to joining NextCure, Dr. Myint held senior roles at both Celgene and NexImmune.Dr. Myint has over 20 years of experience in both academia and
Seekingalpha · 01/14 21:14
Dr. Han Myint Appointed as NextCure's Chief Medical Officer
NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD,...
GlobeNewswire · 01/14 21:05
Dr. Han Myint Appointed as NextCures Chief Medical Officer
BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, to...
GlobeNewswire · 01/14 21:05
*DJ NextCure Says Han Myint Appointed as Company's Chief Medical Officer >NXTC
Dow Jones · 01/14 21:05
NextCure provides update on NC318 clinical program
NextCure ([[NXTC]] -11.1%) provides an update on the clinical trial program for NC318, its first-in-class immunomedicine against Siglec15 (or S15), a novel immunomodulatory target.An ongoing Phase 2 trial is being modified
Seekingalpha · 12/17/2020 14:39
NextCure Provides Updates On NC318 Clinical Program; Says At This Time, No Longer Plans To Initiate Study Of NC318 In Combination With Chemotherapy
BELTSVILLE, Md., Dec. 17, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat
Benzinga · 12/17/2020 12:08
NextCure Provides Updates on NC318 Clinical Program
GlobeNewswire · 12/17/2020 12:05
NextCure (NXTC) in Focus: Stock Moves 7.6% Higher
Zacks · 12/14/2020 13:35
Is NXTC A Good Stock To Buy Now?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and no...
Insider Monkey · 12/14/2020 12:07
NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference
BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference on December 1st. An audio webcast of the pre-recorded fireside chat will be available through the Investors section of the company’s website at www.nextcure.com and archived on the website for 30 days.About NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.comCautionary Statement Regarding Forward-Looking Statements Statements made in this press release that are not historical facts are forward-looking statements. Words such as “expects,” “believes,” “intends,” “hope,” “forward” and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure’s plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including NextCure’s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change. CONTACT: Investor Inquiries Timothy Mayer, Ph.D. NextCure, Inc. Chief Operating Officer (240) 762-6486 IR@nextcure.com
GlobeNewswire · 11/23/2020 21:05
NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference
BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, to...
GlobeNewswire · 11/23/2020 21:05
The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24)
Benzinga · 09/25/2020 11:37
NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors
BELTSVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of John G. Houston
GlobeNewswire · 09/14/2020 21:05
NextCure to Present at Morgan Stanley Virtual 18th Annual Global Healthcare Conference
BELTSVILLE, Md., Sept. 08, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the Morgan
GlobeNewswire · 09/08/2020 13:05
What's Next For NextCure
Today, we look at a small biotech concern that has entered 'Busted IPO' territory after a recent trial setback.
Seeking Alpha - Article · 08/24/2020 18:03
NextCure EPS misses by $0.03
NextCure (NASDAQ:NXTC): Q2 GAAP EPS of -$0.53 misses by $0.03. Cash, cash equivalents and marketable securities of $309.3M. Press release
seekingalpha · 08/07/2020 01:50
NextCure Reports Second Quarter 2020 Financial Results
BELTSVILLE, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today
GlobeNewswire · 08/06/2020 20:03
NextCure to Present at BTIG Virtual Biotechnology Conference
BELTSVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today
GlobeNewswire · 08/05/2020 12:05
Will NextCure, Inc. (NXTC) Report Negative Q2 Earnings? What You Should Know
NextCure, Inc. (NXTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 08/03/2020 16:31
A Stock-Picker's Guide To Benjamin Graham's Screening Rules
Seeking Alpha · 08/01/2020 09:46
Webull provides a variety of real-time NXTC stock news. You can receive the latest news about NextCure through multiple platforms. This information may help you make smarter investment decisions.
About NXTC
Nextcure Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. The Company uses its functional integrated nextcure discovery in immune oncology (FIND-IO) technology to functional screening approaches for the identification of targets from multiple therapeutic areas, including autoimmunity and neurology, enabling immunomedicine to treat unmet medical needs. Its product pipelines include NC318, a immunotherapeutic against a immunomodulatory target found on a restricted set of myeloid and tumor cells, and NC410, a immunomedicine designed to block an immune regulator expressed on T cells and suppressive antigen-presenting cell populations, including dendritic cell subpopulations.
More